Yao et al. reported that patients with anti-NMDAR AE, anti-LGI1 AE, and anti-Caspr2 encephalitis all achieved effective seizure control within 2 years after concurrent immunotherapy and ASMs, whereas only 55% of patients with anti-GABABR AE had effective seizure control at the last follow-up visit after 2 years (21). The gene discussed is CNTNAP2; the disease is encephalitis.